Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Tempus AI

Tempus AI Is a Buy, If You Can Handle the Volatility

Tempus AI is well-positioned to capitalize on its extensive clinical data database. It can provide personalized treatment for hard-to-treat illness.

Tempus AI Reverses 192% Run. Why At Least One Analyst Remains A Believer.

Tempus AI Reverses 192% Run. Why At Least One Analyst Remains A Believer.

Tempus AI stock crashed Tuesday as investors questioned the medical AI company's long-term growth prospects.

Investors Business Daily

Nancy Pelosi's Tempus AI Stock Investment Jumps Over 300% in 40 Days

Nancy Pelosi's Tempus AI Stock Investment Jumps Over 300% in 40 Days

Pelosi's Tempus AI call options contracts tripled in value in 40 days as the healthcare firm continued its upward rally on AI-product launches and active collaborations to battle diseases like cancer.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Conflicting Signals: Tempus AI's Stock Market Rally

Tempus AI's stock has soared on completed acquisitions and product launches, yet mixed analyst sentiment signals a need for careful investor review.

Health-Tech Revival: 3 Stocks Set for a Big 2025 Rebound

Check out these three health-tech stocks with prospects of recovery in 2025 after seeing shares decline significantly in 2024.

Pelosi Bets Big on AI: This Is What You Need to Know

Congressional Whale Nancy Pelosi is in the spotlight, buying significant positions in tech stocks like NVDA and other AI plays.

Pelosi Sells 31K Apple and 10K Nvidia Shares, Eyes New AI and Utility Firm in a Major Portfolio Reshuffle

Pelosi sold Apple and Nvidia shares while betting on Tempus AI and Vistra Corp. She also bought call options for both Amazon and Alphabet Class A stocks.

International Business Times UK

inkl

Read news from The Economist, FT, and more,
with one subscription

Tempus AI: A Potential Double-Bagger After Recent Pullback

Tempus AI: A Potential Double-Bagger After Recent Pullback

AI healthcare stock Tempus AI has seen its value fall off a cliff recently. However, Wall Street remains bullish, seeing significant upside in the shares.

1 AI Stock Cathie Wood Is Buying Instead of Tesla

1 AI Stock Cathie Wood Is Buying Instead of Tesla

Cathie Wood is shifting away from Tesla, zeroing in on an AI-driven healthcare firm that is revolutionizing precision medicine and advanced diagnostics.

Stocks To Watch: Tempus AI Sees Relative Strength Rating Rise To 88

Stocks To Watch: Tempus AI Sees Relative Strength Rating Rise To 88

A Relative Strength Rating upgrade for Tempus AI shows improving technical performance.

Investors Business Daily

Stocks To Watch: Tempus AI Sees Relative Strength Rating Rise To 82

Stocks To Watch: Tempus AI Sees Relative Strength Rating Rise To 82

Tempus AI sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

Tempus AI Clears Technical Benchmark, Hitting 90-Plus RS Rating

Tempus AI Clears Technical Benchmark, Hitting 90-Plus RS Rating

Tempus AI shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Tempus AI Shows Market Leadership With Jump To 85 RS Rating

Tempus AI Shows Market Leadership With Jump To 85 RS Rating

Tempus AI sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

Tempus AI Shows Improved Relative Price Performance; Still Shy Of Benchmark

Tempus AI Shows Improved Relative Price Performance; Still Shy Of Benchmark

Tempus AI shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

A Relative Strength Rating upgrade for Tempus AI shows improving technical performance.

Should You Follow Cathie Wood Into This AI Diagnostics Stock?

This AI diagnostics stock is a holding in Wood's ARKK and ARKG ETFs.

People

130,018 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Amazon.com Inc.

Elevance Health

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

290,282 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play